Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

Executive Summary

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

You may also be interested in...



Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA

Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA

Premarin Memory Data Mixed On Dementia Risk; 91% Of Rxs For Menopause

Prescriptions for Wyeth's Prempro and Premarin have almost completely shifted to the relief of vasomotor symptoms in the two years since the first publication of negative findings from the Women's Health Initiative

Related Content

UsernamePublicRestriction

Register

PS041915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel